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Background: Despite the efforts of the healthcare community to improve the quality of diabetes care, about 50%
of people with type 2 diabetes do not reach their treatment targets, increasing the risk of future micro-and
macro-vascular complications. Diabetes self-management education has been shown to contribute to better disease
control. However, it is not known which strategies involving educational programs are cost-effective. Telehealth
applications might support chronic disease management. Transferability of successful distant patient self-management
support programs to the Belgian setting needs to be confirmed by studies of a high methodological quality. “The
COACH Program” was developed in Australia as target driven educational telephone delivered intervention to support
people with different chronic conditions. It proved to be effective in patients with coronary heart disease after
hospitalization. Clinical and cost-effectiveness of The COACH Program in people with type 2 diabetes in Belgium needs
to be assessed.
Methods/Design: Randomized controlled trial in patients with type 2 diabetes. Patients were selected based on their
medication consumption data and were recruited by their sickness fund. They were randomized to receive either usual
care plus “The COACH Program” or usual care alone. The study will assess the difference in outcomes between groups.
The primary outcome measure is the level of HbA1c. The secondary outcomes are: Total Cholesterol, LDL-Cholesterol,
HDL-Cholesterol, Triglycerides, Blood Pressure, body mass index, smoking status; proportion of people at target for
HbA1c, LDL-Cholesterol and Blood Pressure; self-perceived health status, diabetes-specific emotional distress and
satisfaction with diabetes care. The follow-up period is 18 months. Within-trial and modeled cost-utility analyses, to
project effects over life-time horizon beyond the trial duration, will be undertaken from the perspective of the health
care system if the intervention is effective.
Discussion: The study will enhance our understanding of the potential of telehealth in diabetes management in
Belgium. Research on the clinical effectiveness and the cost-effectiveness is essential to support policy makers in future
reimbursement and implementation decisions.
Trial registration: Belgian number: B322201213625. ClinicalTrials.gov Identifier: NCT01612520
Keywords: Type 2 diabetes mellitus, Telenursing, RCT, Economic analysis* Correspondence: irina.odnoletkova@mloz.be
1University of Leuven, Kapucijnenvoer 33, Leuven B-3000, Belgium
Full list of author information is available at the end of the article
© 2014 Odnoletkova et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Odnoletkova et al. BMC Family Practice 2014, 15:24 Page 2 of 9
http://www.biomedcentral.com/1471-2296/15/24Background
The increasing prevalence of type 2 diabetes poses a
challenge to health care systems. Type 2 diabetes is a
complex illness that requires continuing medical care
and patient self-management education to reduce the
risk of long-term complications [1]. Despite the efforts
of the healthcare community to improve the quality of
diabetes care, about 50% of the population with type 2
diabetes do not reach the guideline recommended treat-
ment targets [1,2]. A recent comparative research of
quality improvement strategies in diabetes care found
that interventions targeting the system of chronic dis-
ease management along with the patient are likely to be
more beneficial than those strategies targeting solely
health-care professionals [3].
Patient education in disease self-management is com-
monly recognized as an essential part of diabetes treat-
ment. It has been shown to improve glycaemic control,
whereby the intensity of the educational program is be-
lieved to be an important predictor of the outcomes
[4-6]. However in Belgium, the majority of people with
type 2 diabetes are not offered coverage of educational
programs. Current evidence of the cost-effectiveness
(CE) of diabetes education is limited due to scarcity of
publications in this area and the poor quality of the
studies [7-9].
A variety of strategies and techniques can be used to
provide adequate education in development of problem-
solving skills in diabetes management. Offered in a
group or individually [10,11]; face-to face or on distance
[12-15]; led by people with or without special profes-
sional training [16,17]; and depending on the curricu-
lum, - educational programs may demonstrate different
results in terms of the clinical and cost-effectiveness.
The complexity of these interventions make it difficult
to detect the direct effect of specific features of patient
education on the outcomes [18,19]. Since a commonly
accepted reporting methodology for interventions in
prevention and health promotion within clinical trials is
lacking, patient education programs are frequently poorly
described and difficult to reproduce in other settings.
“The COACH Program” is a well-established target-
driven telephone intervention delivered by nurses or die-
ticians who undergo special additional training [20]. It
showed to effectively reduce the disease related risk fac-
tors in patients with established coronary heart disease
after hospitalization [21,22]. After a research phase, The
COACH Program became operational in Australia and
extended its curriculum to ten different chronic condi-
tions including type 2 diabetes, in the past 15 years. The
clinical and cost-effectiveness of The COACH Program
has not yet been tested in Europe.
The specific aims of the study are: 1) to assess whether
The COACH Program can be offered by a sickness fundand delivered in cooperation with caregivers in Belgium;
2) to investigate whether The COACH Program helps
people with type 2 diabetes to achieve better glycemic
control and improved modifiable diabetes risk factors
and self-perceived health compared with usual care alone;
3) to analyze the cost-effectiveness of The COACH Pro-
gram from the perspective of the health care system based
on the trial results extrapolated to a life-long horizon.
Methods/Design
Study design
The study is a parallel-group RCT, in which patients
with type 2 diabetes, affiliated to the Belgian sickness
fund Partena, were selected based on their medication
consumption data, recruited by their sickness fund, and
randomized to receive usual care plus The COACH Pro-
gram or the usual care alone. The study will assess the
difference in outcomes between the two groups. The pri-
mary outcome measure is the level of glycohemoglobin
HbA1c at 6 months after randomization. The secondary
outcomes are: total cholesterol (TC), low-density lipo-
protein (LDL), high-density lipoprotein (HDL), triglycer-
ides (TG), blood pressure (BP), Body Mass Index (BMI),
smoking status; proportion of people at target for HbA1c,
LDL-Cholesterol and Blood Pressure; self-perceived health
status, diabetes-specific emotional distress, and satis-
faction with diabetes care. The follow-up period is 18
months. All outcome measurements will be collected 3
times: before randomization, upon the graduation from
the program (6 months after the program start); and at
the end of the follow-up period (18 months after ran-
domization). The allocation ratio is 1:1. Within-trial and
modeled cost-utility analyses, - to project effects over a
longer time horizon beyond the trial duration, - will be
undertaken from the perspective of the health care system
if the intervention is effective.
Study participants
Study participants are adults between 18 and 75 years
old with a diagnosis of type 2 diabetes taking glycaemia
lowering oral and/or injectable medications. Exclusion
criteria are people on corticoid therapy and/or with a
debilitating coexisting medical condition such as dialysis,
mental illness, cancer; residents of long term care facil-
ities; pregnant women; and people incapable of tele-
phone communication in Dutch.
Coaching intervention
The COACH Program consists of 5 monthly telephone
sessions of 30 minutes on average delivered by certi-
fied diabetes nurse educators (further referred to as
“coach”). Prior to the intervention, they undergo 5-
days training in up-to date clinical guidelines on dia-
betes self-management and how to give patients the
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ches are also trained in the use of the COACH Program
software for patient administration. Coaches use patient’s
baseline data obtained during the first home visit, to assess
the individual risk profile and to suggest targets for dia-
betes risk factors based on the Flemish and international
guidelines for good practice in diabetes care [1,23-25].
The therapeutic goals are discussed with the GP by phone
before the first coaching session.
Prior to the beginning of the coaching, patients of the
intervention group receive a welcome package with in-
formation about the program, a book with advice on
nutrition in diabetes and a waist circumference meter
with a BMI calculator. Patients with HbA1c above 6%
(42 mmol/mol) at baseline, who are not in possession of
an insurance-covered meter for self-monitoring of blood
glucose (SMBG), receive a SMBG set including lancets
and strips.
All risk factors associated with diabetes are addressed
by the coaches, - glycaemia, lipids, blood pressure, kid-
ney, foot and eye checks, nutrition, physical activity,
smoking and alcohol consumption. Patients are instructed
on how to perform SMBG and interpret the results. A
measurement frequency of one or two day profiles a week
is advised. Depending on the type of the diabetes medica-
tion – causing hypoglycemia or not – a scheme of four or
two times a day respectively is recommended. Considering
special skills needed to assist people in smoking cessation,
smokers of the intervention group are motivated to contact
the tobaccological service of the Belgian Cancer Federation
“Tabakstop” that offers tailor-made telephone sessions and
is free for all patients.
The coach registers and monitors the biomedical risk
factors, the lifestyle/behavioral parameters and the use
of the recommended medications. The COACH Pro-
gram software supports advice on individual treatment
targets and the frequencies for the diabetes risk factors
control. The software also helps to quickly generate a
written coaching report with actual advice and compari-
son of the current status of the risk factors against the
individual treatment targets. These reports are sent to
the patients and copied to their GP’s by e-mail or post.
The COACH Program software is built upon several da-
tabases, such as reimbursed medications and standard
comments for each diabetes risk factor.
The COACH Program trains patients to ‘drive’ the
process of achieving and maintaining the target levels
for their risk factors while working in association with
their GP. Coaching is focused on eliminating the
knowledge and treatment gap and motivating the pa-
tient to apply the appropriate lifestyle and medical
therapy. Each session is used as the foundation for the
next contact. The coaching model is a continuous five-
stage coaching cycle: stage 1 - finding out what the patientknows; stage 2 - telling the patient what he/she should
know; stage 3 - assertiveness training; stage 4 - setting an
action plan; stage 5 - reassessment at the next coaching
session (monitoring). Patients are invited to contact their
coach between coaching sessions for questions and further
information if required.The control group
The control group receives usual care alone. In Belgium,
patients on oral glycaemia lowering medications are pre-
dominantly treated by their GPs. When insulin therapy
needs to be initiated patients become entitled to a “dia-
betes care trajectory” reimbursed by the national health
insurance. The care trajectory is initiated by the GP and
implies coordinated care, including diabetes education
by a certified diabetes educator, and a yearly contact
with an endocrinologist, in addition to the regular GP
visits. Patients with advanced diabetes, in need of three
or more insulin injections per day, are normally treated
in a hospital setting by an endocrinologist, with support
of a multidisciplinary team.
All study participants, including the control group, re-
ceive a DVD with educational material on type 2 dia-
betes, its complications and lifestyle recommendations.
The laboratory results of the blood analysis are mailed
to all study participants and their GPs after each
assessment.Patient recruitment and randomization
Patients were selected from the administrative database
of the sickness fund “Partena” which belongs to the
Group of the Independent Sickness Funds, based on the
reimbursement data of glycaemia lowering medications
in the past 12 months. Prior to the start of patient re-
cruitment, their GP’s were informed about the study by
mail. Selected patients were sent a letter of invitation to
participate in the study and invited to express their
interest by returning an attached response card. Those
candidates who expressed their interest, or have not
reacted to the invitation within two weeks, were con-
tacted by phone. A home visit for the baseline assess-
ment was scheduled with those patients who confirmed
their participation. The assessment visit was carried out
by a nurse not involved in the intervention delivery.
Randomization was performed every 2 weeks on aver-
age. To achieve a comparable HbA1c distribution within
both groups, patients were stratified based on the base-
line level of HbA1c: with HbA1c < 7% (53 mmol/mol),
or with HbA1c ≥ 7%. Patients from both strata’s were al-
located to the intervention or the control group by a
data analyst of the Independent Sickness Funds, further
not involved into the study, by using a random number
generator programmed in Excel.
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During the assessment visits, the nurses register data as
stated in Table 1. Weight is measured by electronic
scale, patients wearing light indoor clothing, no shoes.
Height is measured in the standing position using a
portable anthropometer, feet, knees, buttocks and shoul-
der blades in contact with the vertical surface, no shoes.
Waist circumference is measured with a measuring tape
according to the guidelines of the Belgian Association
for the Study of Obesity [26]. Blood pressure is taken in
a sitting position by using a manual sphygmomanom-
eter. Two measurements are taken, the lower systolic
and diastolic measurements will be used in the analysis.
The level of toxic carbon monoxide (CO) is measured inTable 1 Patient data collection at three assessment moments





Diabetes 2 since Self-reporting
Comorbidities: Self-reporting
Cardiovascular: CHD; heart failure; atherosclerosis;
past MI; stroke; TIA
Respiratory: COPD; asthma
Other: hypoglycemia; hypertension; dyslipidemia;
Kidney disease; neuropathy; depression
Family history of type 2 diabetes and cardiovascular disease Self-reporting
Blood pressure Home visit te
Height Home visit te
Weight Home visit te
BMI Calculated
Waist circumference Home visit te
Prescribed medications Sickness fund
self- reporting
Smoking Self-reporting
Lifestyle: physical activity; alcohol consumption;
healthy eating
Self-reporting
Diabetes risk factor knowledge test Self-reporting
EQ-5D Self-reporting
PAID Self-reporting
DTSQ – status version Self-reporting
HbA1c Pathology lab
Lipid profile: TC; HDL; LDL; TG Pathology lab
Satisfaction about the COACH program (Intervention group) Self-reporting
Costs Sickness fund
time& materia
Abbreviations: CHD Coronary Heart disease, MI Myocardial Infarction, TIA Transient Is
dimension health status questionnaire, PAID Problem Areas in Diabetes Questionnaire,
TC total cholesterol, HDL high-density lipoprotein, LDL law-density lipoprotein, TG triglyparts per million (ppm) by a CO meter in addition to
self-reporting smoking status.
The patients are asked to fill in the EQ-5D 3-L as a gen-
eric health status survey, the questionnaire Problem Areas
in Diabetes (PAID) that measures the level of diabetes-
specific emotional distress, and the Diabetes Treatment
Satisfaction Questionnaire (DTSQ). All chosen instru-
ments have a well-established cross-cultural validity. In
addition, patients in the intervention group are asked to
fill in a specific satisfaction questionnaire about The
COACH Program. The blood samples are collected and
delivered to the laboratory “Meidina Medische Analysen”
contracted for the period of the trial. For the biomedical
analyses the following methods are used: HbA1c – by ionduring the trial
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chemic Attack, COPD Chronic Obstructive Pulmonary Disease, EQ-5D EuroQol 5
DTSQ Diabetes Treatment Satisfaction Questionnaire; HbA1c glycohemoglobin,
cerides.
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colorimetric methods; HDL – through neutralization of
LDL and VLDL. The LDL is calculated using the Friede-
wald equation. Table 1 summarizes the protocol of patient
data collection during the trial.
Sample size
Sample size calculation was performed by using the stata
software. For the subgroup of people with HbA1c ≥ 7%:
assuming the difference of 0.4% between the control and
intervention group (7.8% vs 7.4%) [4] and the standard
deviation of 0.94% as observed within this subgroup at
the baseline data analysis, we would need 232 people in
both arms to achieve a power of 0.90 in this subgroup.
46% of the participants represent this group. This means
that recruiting 555 people in total would be enough to
power our hypothesis for the subgroup of people with
HbA1c ≥ 7% at baseline if accounting for up to 10%
drop-out.
For the total study population: based on the assump-
tion that the mean difference in HbA1c between two
groups will be of 0.3% (7.0% vs 6.7%) [2], and standard
deviation of 1.05% - as analyzed at baseline – to achieve
a power of 0.90 with alpha being 0.05, we would require
514 subjects to complete the study. Allowing for a drop-
out rate of up to 10%, the target recruitment number
should be 566 patients totally, or 283 patients in each
arm [27].
Monitoring intervention integrity
To keep track on the degree to which The COACH Pro-
gram is delivered as initially planned and to monitor the
compliance of the patients and their GPs to the advice
of the coaches, the following measures are foreseen: 1)
all written coaching reports are reviewed by IO and the
head nurse during the first two months of the intervention
and selectively thereafter; 2) several coaching sessions are
audio-recorded; 3) the coaches register patient’s and GP’s
compliance to their advice, particularly in adjusting medi-
cation therapy.
Cost-utility analysis
Cost-utility analysis will be performed if the clinical
study demonstrates a positive difference in clinical end
points between two study groups [28,29]. Within-trial
and modeled cost-utility analyses will be undertaken
from the perspective of the health care system, i.e. taking
into account direct health care costs to the system in-
cluding both the cost for the health insurance as the pa-
tient out-of pocket costs [30].
The incremental cost-effectiveness ratio (ICER) will be
calculated by using the following equation: ICER =
ΔCosts/ΔQALYs, where ΔCosts is the difference be-
tween the mean total cost in the intervention and thecontrol group and ΔQALY is the area between two
curves depicting the evolution of the means in QALYs-
utilities over time in the intervention and the control
group.
Modeling will be applied for projecting effects ob-
served within the trial over a life-time horizon. The
assumptions on the progression of type 2 diabetes de-
pending on the known intermediate surrogate outcomes
and the associated health status will be derived from
published sources. The model’s outcomes validity will be
tested through critical appraisal by experts. Future costs
of type 2 diabetes without complications, and costs asso-
ciated with each fatal or non-fatal diabetes-related com-
plication will be estimated based on the epidemiological
data available in Belgium and the database of the Inde-
pendent Sickness Funds. Future costs will be discounted
at 3%, future QALYs gained at 1.5% per annum [30].
ICERs will be calculated at various time horizons (e.g., 2,
5, 10, 20 years) [30].
Costs of the intervention
The fixed intervention costs consist of the investment
into the program development, the administrative and
supporting personnel, the software maintenance, the
consultancy services, and the overhead. Variable costs
are those costs which are directly dependent on the
number of patients served by the program and associ-
ated with the training of the coaches, the recruitment of
patients into the program, the actual coaching and ad-
ministration time, once-off per patient fee, and produc-
tion and distribution of the program materials for
coaches and patients. All costs will be registered pro-
spectively during the trial based on the individual time
and material registration and the contractual prices.
Fixed costs will be allocated to patients through dividing
the total fixed costs by the number of participants in the
intervention group.
Within trial costs and health utilities analysis
Information on the utilization of healthcare services will
be obtained from the database of the Independent Sick-
ness Funds. The health care services include primary
care visits, visits to emergency departments, visits to
specialists, hospital stays, medications, laboratory tests,
imaging techniques, paramedical care and other thera-
pies. Out-of-pocket costs will be derived from the
published reimbursement regulations. All cost items de-
scribed above will be specified and expressed in physical,
and in monetary units (Euro’s). As baseline measure of
costs in both groups, the costs of health care consump-
tion in the 12 months period prior to the trial will be
taken. Diabetes – and non-diabetes related costs will be
distinguished. Costs imposed by the study that are not
part of the routine practice, such as protocol-driven
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included into the cost analysis.
The health utility weights will be derived from the
Flemish utility value system based on the EQ-5D scores
obtained during the assessments visits [30]. QALYs asso-
ciated with the future diabetes complications will be de-
rived from published sources. QALYs will be calculated
assuming linear interpolation between measurement
points and calculating the area under the curve, to give
a number of QALY gained per patient over the trial
period [29].
Statistical analysis
The two-tailed unpaired t-test will be used for continu-
ous data and chi-square test for proportions. Where ap-
propriate, regression analysis will be applied to account
for baseline differences between the two study groups.
The results will be expressed as mean (95% CI) for nor-
mal data and median (range) for skewed data. Sensitivity
analysis will examine the effect of loss to follow-up on
the intervention effect. The analysis will be conducted
by intention to treat, which means, all patients will be
followed for the full duration of the trial. Exploratory
analyses will examine the effect of other factors, such as
socio-demographic variables, on the outcome.
ICERs will be calculated for the mean and for the
upper and lower confidence levels of marginal costs and
utilities. One-way sensitivity analysis will be performedInvited into the stu









Figure 1 RCT flowchart including the numbers of the enrolled and rato test the relative contribution of different variables to
the uncertainty around ICER and presented by means of
a Tornado diagram. Probabilistic sensitivity analysis
(Monte Carlo simulation) will be performed for all
model inputs. The structural uncertainty will be tested
through presenting different model scenarios. The re-
sults of this analysis will be presented on the cost-
effectiveness plane. Probability of willingness to pay by
the Belgian Health Care system will be forecasted and
presented as a cost-effectiveness acceptability curve [30].
Ethical issues
For the patient detection procedure based on the medi-
cation consumption data, an approval has been obtained
from the Belgian Commission for the protection of Priv-
acy. The study protocol has been approved by the Eth-
ical Committee of the University Hospital of Leuven
prior to the beginning of the recruitment. Written in-
formed consent was obtained from all patients before
initiation of the study. The study is registered at Clini-
calTrials.gov, identifier: NCT01612520.
Patient recruitment and baseline data
Between April 2012 and June 2013, 3115 affiliates of the
sickness fund Partena were identified based on the reim-
bursement data and invited into the study. 685 (22%)
agreed to participate. 574 were eligible and took part in
the baseline assessment. Figure 1 shows the RCT flowchartdy (n=3115)
Excluded  (n=2541 )
Have not responded or declined
(n=2431)
Not meeting inclusion criteria (n=110)
Allocated to usual care (n=287)
on
is







Table 2 Baseline clinical characteristics of patients in the







Male 173 (60) 180 (63)
Female 114 (40) 107 (37)
Age, years
Mean (SD) 63.8 (8.7) 62.4 (8.9)
Median (range) 65.9 (35–75) 63.9 (35–75)
HbA1c, % (mmol/mol) 7.0 (53) 7.0 (53)
Mean SD 1.1 (12) 1.0 (11)
Total cholesterol, mg/dl mean (SD) 173 (37) 178 (39)
LDL-C, mg/dl mean (SD) 93 (31) 97 (32)
HDL-C, mg/dl mean (SD) 52 (19) 51 (14)
Triglyceride, mg/dl median (range) 127 (42–1369) 130 (35–1993)
Systolic blood pressure, mmHg
mean (SD)
133 (18) 132 (17)
Diastolic blood pressure, mmHg
mean (SD)
75 (10) 76 (10)
BMI (kg/m2) mean (SD) 30 (5) 31 (5)
People at treatment target, no (%)
HbA1c < 7% (53 mmol/mol) 155 (54) 159 (55)
LDL-C < 100 mg/dl 172 (60) 164 (57)
SBP < 140 mmHg 174 (61) 186 (65)
DBP < 80 mmHg 160 (56) 160 (56)
At target for all above risk factors 40 (14) 46 (16)
BMI < 25 kg/m2 33 (11) 28 (10)
In the subgroup with HbA1c≥ 7%
(53 mmol/mol)
HbA1c, % (mmol/mol) 7.9 (63) 7.8 (62)
MeanSD 1.0 (11) 0.8 (9)
Self-reported
Diagnose type 2 diabetes since, no (%)
≤ 2 years 46 (16) 41 (14)
≥ 10 years 94 (33) 91 (32)
Smokers, no (%) 40 (14) 54 (19)
People with 1st grade relatives with
known type 2 diabetes, no (%)
159 (56) 139 (49)
People with 1st grade relatives with
cardiovascular disease diagnosis
before 60 y.o., no (%)
93 (33) 90 (32)
With regular hypoglycemia, no (%) 26 (9) 36 (13)
People with other chronic condition(s),
no (%)
211 (74) 217 (76)
Coronary heart disease 35 (12) 39 (14)
Atherosclerosis 19 (7) 9 (3)
Heart failure 21 (7) 14 (5)
Table 2 Baseline clinical characteristics of patients in the
COACH program and usual care groups (Continued)
Past MI 11 (4) 14 (5)
Past stroke 11 (4) 4 (1)
Past TIA 8 (3) 5 (2)
COPD 11 (4) 15 (5)
Asthma 13 (5) 19 (7)
Hypertension 111 (39) 113 (39)
Dyslipidemia 81 (28) 80 (28)
Kidney disease 17 (6) 10 (3)
Depression 19 (7) 24 (8)
Neuropathy 10 (3) 16 (6)
Having physical activity* of 30 minutes
at least 5 days per week, no (%)
170 (59) 159 (55)
Having daily healthy diet**, no (%) 181 (63) 157 (55)
*Physical activity is moderate aerobic activity at 50–70% of maximum heart
rate (1).
**Healthy diet (HD) means regular meals spread evenly throughout the day,
low in fat, particularly saturated fat, and sugar and based on high fiber
carbohydrate foods. HD implies daily consumption of at least two pieces of
fruit and 300 g vegetables.
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tients. Table 2 summarizes the baseline characteristics of
people allocated to the intervention and control groups.
Discussion
Local context can have impact on the acceptability of
new forms of care and on their clinical- and cost-
effectiveness. Telephone coaching has been applied for
patient education in USA and Australia since 1990-ties
and has a potential to increase access to health care ser-
vices. However, in systematic reviews on telehealth in
chronic disease management, European studies are
poorly represented [13,14,20]. It is therefore important
to investigate the transferability of successful telehealth
interventions to European countries through studies of a
high methodological quality. To increase the added value
of such research to patients and policy makers, study de-
signs have to consider the clinical effectiveness, the cost-
effectiveness and the implementation potential.
The design of our study has several strengths. 1) The
intervention integrity analysis is integrated into the study
protocol. The verification of program integrity should be
part of the evaluation of any behavioural intervention as
lowered adherence to the protocol is often associated
with poorer outcome [31]. The integrity assessment also
reveals important information about the feasibility of the
intervention in real life settings. 2) The COACH Pro-
gram is well-established in Australia, which enables a
comparison of the clinical outcomes in relation to the
integrity results. 3) Patients were invited into the study
directly, reducing the potential of selection bias. 4) The
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help the policy makers to prepare well informed reim-
bursement decisions. 5) The database of the sickness
funds is a reliable and comprehensive source of informa-
tion on health care consumption.
However, a number of design limitations need to be
mentioned. 1) The research setting will to a certain ex-
tent affect the study results. Several elements of the
protocol are not part of the usual care, e.g. home visits
for the purpose of the data collection including the add-
itional laboratory analysis. 2) In the within trial cost-
utility analysis, incremental QALYs is one of the primary
endpoints of the economic evaluation but can only be
derived from a number of generic health surveys with a
limited capacity in detecting minor differences in health
status, at least in the short term. The disease specific
questionnaires have shown to be more sensitive and
relevant for use in certain interventions and patient
groups. In the last years, researchers have been develop-
ing algorithms to translate the scores obtained from dis-
ease specific health status questionnaires into health
utility weights. However the performance of these algo-
rithms have been criticized [32]. Further research in health-
economics should focus on development of cross-cultural
instruments capable of capturing common measures of
well-being with a higher grade of sensitivity to minor con-
dition divergences.
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